Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3

28 August 2026 (16:30 - 16:45)

Organised by:

Video

Sign in for access options

About the speaker

Associate Professor Luke Joseph Laffin

Cleveland Clinic, Cleveland (United States of America)

3 More presentations in this session

Presentation thumbnail

Angiopoietin-like 3 antibody rivocibart for homozygous familial hypercholesterolemia

Professor D. Peng (Changsha, CN)

Presentation thumbnail

AAV8-mediated gene therapy for homozygous familial hypercholesterolemia

Doctor T. Li (Xi'an, CN)

Presentation thumbnail

Extremely Long Duration Lp(a) Reduction Following a Single Dose of Kylo-11: Final Data from a First-in-Human Study

Doctor A. Sarraju (Cleveland, US)

Access the full session

Session thumbnail

Late-Breaking Clinical Trials: rewriting cardiovascular disease on gene and molecular therapies

The Event

Event poster

ESC Congress 2026

28 August 2026 16:30 CET

You may be interested in

Congress Presentation

Can gene editing address unmet need in dyslipidaemia?

30 August 2025

Congress Presentation

SHR-1918, a monoclonal antibody against angiopoietin-like 3, in healthy subjects: a randomized, double-blind, placebo-controlled, phase 1 study

1 September 2024

Congress Presentation

CMR outcomes following one-time in vivo CRISPR editing with nexiguran ziclumeran in patients with ATTR-CM: phase 1 results

11 May 2026

Congress Presentation

Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal

30 August 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources